Background {#Sec1}
==========

The foot deformity pes planovalgus can cause symptoms or complaints, and may lead to dysfunction and functional limitation \[[@CR1]--[@CR3]\]. It can be an acquired entity where weakness of the plantarflexors and invertors of the foot (mainly the tibialis posterior muscle) cause a flexible or rigid flatfoot deformity \[[@CR4], [@CR5]\].

The posterior tibial tendon/muscle primarily serves as a dynamic stabiliser of the foot's medial longitudinal arch \[[@CR6]\]. Excessive stress can lead to tendinopathy of the posterior tibial tendon. This leads to posterior tibial tendon dysfunction (PTTD). Therefore, PTTD is most often accompanied by pes planovalgus foot deformity. Because of the mutual prevalence of both aspects, it is not clear if the muscle-tendon dysfunction is a result of the foot deformity \[[@CR7], [@CR8]\], or if it is causative for foot deformation \[[@CR9], [@CR10]\]. There is consensus that PTTD and pes planovalgus are closely connected \[[@CR11]--[@CR15]\].

Patients with PTTD and concomitant pes planovalgus report pain around the medial malleolus in the tibialis posterior muscle and its tendon. As the condition progresses, they can exhibit plantar hyperkeratosis in the talus area and lateral impingement at the fibula-calcaneal transition \[[@CR2], [@CR14], [@CR15]\].

PTTD can be divided into four stages according to Johnson & Strom \[[@CR2]\]. Stage I and II comprise a still flexible foot structure, which is considered to be eligible for non-surgical treatment. Stage III and IV contain already rigid longitudinal arch flattening with a tear of the spring ligament complex and talar valgus tilt in the ankle mortise \[[@CR16]\]. Here, active compensation is not able to take place \[[@CR17], [@CR2]\].

As long as PTTD and the foot deformity demonstrate no symptoms, treatments are basically considered unnecessary \[[@CR18]\]. If patients do have symptoms, however, a variety of therapy options may be administered: foot orthoses, ankle foot orthoses, stabilising tape, exercise (training therapy with, for example, eccentric exercise), pain medication and/or anti-inflammatory medication and patient education \[[@CR11], [@CR12], [@CR15]\].

Optimisation of foot loading management by means of foot orthoses and adequate footwear is the most important aspect in therapy. Depending on the progression of the pathology, this can be progressively managed with over-the-counter non-individualised foot orthoses, then with individualised foot orthoses and finally with semi-rigid ankle foot orthoses \[[@CR19]\]. These recommendations are published in clinical guidelines, but few high-quality studies have investigated their efficacy \[[@CR11], [@CR12]\].

Poor quality studies with a variety of uncontrolled interventions (foot orthoses, ankle foot orthoses, strengthening exercises, custom footwear, medication, ice, mega pulse and ultrasound -- isolated or combinations) report possible benefits, but the lack of high quality, robust evidence does not allow conclusions for clinical practice \[[@CR1], [@CR20]--[@CR22]\]. The only high-quality randomised controlled trial in patients with PTTD (and pes planovalgus) found that patients benefit most from a combination of foot orthoses and exercise after a 12-week intervention period \[[@CR15]\].

Aside from clinical outcomes, functional impairments and their possible changes through interventions are not described in the literature on the basis of biomechanical measurements. Most often, static alignment measures of foot structure like 'navicular drop' as a composite for excessive pronation and/or longitudinal arch flattening are used to quantify flatfoot alignment \[[@CR23], [@CR24]\].

However, dynamic measurement is more valid because dynamic foot motion is not strongly associated with static alignment \[[@CR23], [@CR24]\]. Studies on foot kinematics between flat-arched feet and controls shows that foot function and arch flattening can be quantified with multi-segment foot models during weightbearing \[[@CR25], [@CR26]\]. Therefore, assessing foot structure during dynamic movement seems to be the current consensus \[[@CR26]--[@CR28]\].

Evaluations of neuromuscular function are very rare. A study investigating neuromuscular activity of the tibialis posterior muscle reports enhanced activity in flat-arched asymptomatic people during stance \[[@CR29]\]. Tibialis posterior and peroneus longus muscle activity with the use of foot orthoses in flat-arched people changed \[[@CR30]\], which is in contrast to O'Connor et al. who report that the tibialis posterior showed (at least in running motion) inconclusive activation patterns and no changes between different shoe conditions \[[@CR31]\]. Another study showed reduced peroneus, lateral and medial gastrocnemius, and soleus muscle activity during early stance but enhanced tibialis anterior muscle activity in participants with asymptomatic flatfoot but with a history of musculoskeletal pain compared to controls \[[@CR32]\]. This underlines the importance of readily available neuromuscular parameters describing gait function \[[@CR33]--[@CR35]\].

Some recent studies present sophisticated measurement approaches of dynamic foot function in pes planovalgus but to the authors' knowledge, no study to date has evaluated dynamic foot function in patients suffering from acute complaints. Most studies use healthy controls or asymptomatic flatfooted subjects \[[@CR36], [@CR23], [@CR37]\]. This makes it difficult to draw clear conclusions with regard to patients.

The aims of this study are therefore to: (i) analyse the efficacy of three different non-surgical therapy regimens in PTTD patients, and (ii) evaluate descriptively functional outcome with a comprehensive biomechanical measurement approach to learn more about functional changes in movement generation and its possible plasticity throughout the intervention.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The study design is a parallel-group randomised trial with three intervention groups receiving therapy regimens aimed at symptoms associated with pes planovalgus (Fig. [1](#Fig1){ref-type="fig"}). There will be an intervention phase of 12 weeks, which is a common therapy window for the associated symptoms of clinical problems like pes planovalgus \[[@CR38]\]. Participants' pain and functional impairment perception will be measured pre- and post-intervention (and in the middle of the intervention period). Biomechanical measurements (standardised laboratory study) before and after the intervention phase will accompany the protocol to evaluate possible functional changes induced by the therapy regimen.Fig. 1Study flow chart: randomisation of patients to one of three intervention groups: foot orthoses only FOO, foot orthoses and eccentric exercise FOE, sham foot orthoses only FOS

Study population {#Sec4}
----------------

A cohort of 60 participants will be recruited out of six state-wide foot surgery centres. To be included in the trial, participants will have to have: pes planovalgus, accompanying PTTD, associated foot pain; and a flexible foot structure, leading to eligibility for non-surgical treatment. Severe cases of flatfoot deformity indicating surgical correction (e.g., rigid foot structure and not being able to complete the test protocol due to severe pain or impaired physical function) will be excluded.

Specific inclusion criteria are similar to Kulig \[[@CR15]\] and include:Age: 40--70 yearsCurrent complaint of foot and ankle pain that has lasted for three months or moreFlexible pes planovalgus deformity in the clinical assessmentPTTD of stage I and II according to Johnson & Strom \[[@CR2]\]Pes planovalgus foot deformity with longitudinal arch flattening verified by radiograph \[[@CR39]\]: Lateral view: lateral talo-first metatarsal angle ≠ 0° (break of axis): angle \>10° according to Younger et al. \[[@CR39]\], Anteroposterior view: anteroposterior talo-first metatarsal angle ≠ 0° (break of axis): angle \>10° according to Younger et al. \[[@CR39]\]No indication/not yet an indication for surgical treatment of foot deformity

Exclusion criteria are again similar to Kulig \[[@CR38]\] and include:Rigid foot deformityPTTD of stage III and IV according to Johnson & Strom \[[@CR2]\]Cardiac, neurological, peripheral vascular, or musculoskeletal pathologyAcute infection or alcohol addiction limiting participation in study protocolAcute use of local or systemic analgesicsAcute physical therapy, training therapy or physiotherapyAcute overuse or traumatic injury to the lower leg (excluding pes planovalgus associated pathology)Prior surgery to the lower limb

Participants will be included after clarification of inclusion and exclusion criteria by a clinical examination and after comprehensive written and oral information. All participants will have to sign a written informed consent in line with the Ethics Approval obtained from the Ethics Commission of the Canton Berne (Approval number: KEK-Nr. 158/12). Anthropometric data (gender, age, height, weight, shoe size and foot length) will be recorded according to guidelines of 'Good Clinical Practice' in subject specific Case Report Forms \[[@CR40]\]. All subsequent data acquisition will also be documented in the Case Report Forms. This secures quality control of stored data and ensures that every single data item can be tracked down to its origin.

Randomisation {#Sec5}
-------------

Randomisation for group allocation to Foot Orthoses Only (FOO), Foot Orthoses with Eccentrics (FOE) or Sham Foot Orthoses (FOS) will take place with the online tool [www.randomization.com](http://www.randomization.com) (no blocking or stratification will be used). The biomechanical testing (standing, walking and walking down a stairway) will be administered in a fixed sequence since standing posture serves as calibration for dynamic measurements. Group allocation will be conducted using opaque sealed envelopes (i.e., concealed allocation). The allocation list will be stored separately and measurement personnel and data analysing personnel will not be involved in group allocation. Medical doctors, responsible for recruitment and checking of eligibility, will also not be involved in group assignment.

Blinding {#Sec6}
--------

Blinding of the intervention to the participants is not possible as participants will recognise the allocated therapy. The study personnel will refrain from explaining hypothetical effects of foot orthoses, eccentric exercise or sham foot orthoses. The measurement and data analysis personnel will be blinded to group allocation during data acquisition and data analysis. De-blinding will take place after statistical analysis has been completed.

Procedure {#Sec7}
---------

After the clinical examination, participants will be forwarded to the study centre for further anamnestic (medical history) pre-tests. A 1st measurement appointment will then be finalised. Meanwhile, fabrication of the foot orthoses takes place. At the 1st measurement appointment, participants' anthropometrics and static unloaded and loaded foot posture for characterisation will be assessed. Following this, the participants' foot health status (using the Function Index FFI, German Version (or FFI-D) \[[@CR41], [@CR42]\]), functional impairment (using the Pain-Disability-Index PDI \[[@CR43], [@CR44]\]), and current pain perception (using a VAS \[[@CR38]\]) will be assessed. Biomechanical measurements of standing posture, level walking and walking down stairs will then be taken. After biomechanical testing, a re-evaluation of pain assessment with a VAS will be conducted.

After the 1st measurement appointment, an intervention period will follow for 12 weeks. All participants will receive a guideline for load management during the intervention and an activity diary with accompanying assessments (FFI, PDI and VAS after 6 weeks). After the 12-week intervention period, a 2nd assessment of the patient's foot health status (FFI), functional impairment (PDI) and current pain perception (VAS pre/post-test), as well as the biomechanical tests will follow. If symptoms persist at the end of this period, participants will be transferred to the initial foot surgery centre for further medical assessment and possible ongoing therapeutic care.

Interventions {#Sec8}
-------------

After group allocation, all participants will be provided with instructions about their allocated interventions (see below). All participants will receive an educational session where they will be informed about the length of time to resolution of symptoms (realistic anticipation of therapy success), importance of adhering to wearing the foot orthoses, and issues about weight control \[[@CR38]\]. A guideline based on the EdUReP (Education, Unloading, Reloading, Prevention) model, which provides a framework for management of tendinopathy, accompanies the intervention phase \[[@CR45]\].

Participants will receive one of the following therapies according to their random allocation:

### Foot Orthoses Only (FOO) {#Sec9}

Participants in this group will receive custom-made foot orthoses fabricated by the same orthopaedic technician (AR, Ortho-Team AG, Bern, Switzerland). Foot orthoses will be fabricated out of Ethylene Vinyl Acetate (EVA, shore 40) with a thickness at the base of approximately 4 mm. The foot will be cast in a three-dimensional foam box impression in the neutral position of the foot under partial weightbearing \[[@CR46]\]. This neutral position is already a "corrected" position for patients with the mentioned pathology. The 3D foam box impression serves as the basis for implementing correcting elements in the foot orthoses via computer-aided design software (CAD). A medial longitudinal arch is provided for arch support and a bowl-shaped heel is integrated to promote rear foot stability. Finally, the foot orthoses will be fabricated out of an EVA block by means of computerised numerical control technology (CNC). A dynamic barefoot plantar pressure distribution to evaluate dynamic foot function during walking (foot progression angle, forefoot abduction and medial loading) and qualitative gait analysis will be performed to support decision making on the amount of medial arch posting \[[@CR43]\]. A medial longitudinal arch support will increase pressure at the medial plantar surface \[[@CR47], [@CR48]\], which might lead to changes in afferent input triggering neuromuscular control \[[@CR34]\]. A top layer of Alcantara will be glued on top of each orthosis (Table [1](#Tab1){ref-type="table"}). All participants will wear the device throughout the 12-week intervention for a minimum of 80 % of weight-bearing tasks.

### Foot Orthoses and Eccentrics (FOE) {#Sec10}

In addition to the use of the foot orthoses described above, eccentric strengthening exercises will be prescribed in this group (concentric portions are inherent, but emphasis is put on eccentric phases). Heel lowering movements will be performed on the edge of a stair from a calf raised position. For correction of rearfoot eversion a pair of socks will be squeezed between the calcaneii below the medial malleoli (active correction of rearfoot eversion and medial longitudinal arch flattening). This exercise will be performed twice per day with three sets of 15 repetitions per day for 12 weeks. Calf raises will be performed without the squeeze of the pair of socks to reduce load in the concentric phase. The exercise is a modified eccentric version of that proposed by Yuill and MacIntire \[[@CR49]\]. It is combined with the loading suggestions of Alfredson for the treatment of Achilles tendinopathy \[[@CR50], [@CR51]\]. Increasing load (e.g., additional load with back pack) will be performed throughout the intervention as suggested by Jonsson \[[@CR52]\]. Participants will be instructed by an experienced physiotherapist. They will receive an activity booklet to record all training sessions and possible accompanying activities. All participants will wear the foot orthoses throughout the 12-week intervention for a minimum of 80 % of weight-bearing tasks.

### Foot Orthoses Sham (FOS) {#Sec11}

This group will receive individually customised (sham) foot orthoses out of the same material described above. The functional elements of the sham orthoses, like arch support or a bowl-shaped heel to promote rearfoot stability, are designed to assist with blinding of patients. The foot will also be cast in a three-dimensional foam box impression without "correcting" to a neutral position of the foot under partial weightbearing \[[@CR46]\]. The sham orthoses will not receive correcting elements via computer-aided design software (CAD). The sham foot orthoses will also fabricated out of an EVA block by means of computerised numerical control (CNC) technology. Like the other orthoses, a layer out of Alcantara will be glued to the top of the sham orthoses. All participants will wear the device throughout the 12-week intervention for a minimum of 80 % of weight-bearing tasks. The participants in this group will also get an activity booklet to record possible accompanying activity.

All three groups will receive a phone call after one, four and eight weeks to check for compliance, uncertainties and questions (Fig. [1](#Fig1){ref-type="fig"}). If necessary, monitoring sessions for members of the FOE group with the physiotherapist will be organised every four weeks to control exercise execution and to implement training load adjustments \[[@CR52]\]. Where participants experience obvious fitting problems, orthoses will be slightly modified as necessary to ensure comfort and shoe fit.

Outcome measures {#Sec12}
----------------

### Foot-Function-Index (FFI) {#Sec13}

The evaluation of therapy efficacy will be conducted with the main outcome measure, the FFI, before and after the intervention. It will be administered before the biomechanical testing on the pre/post measurements. The FFI is recognised as a valid and reliable tool \[[@CR53], [@CR54]\]. It is also available and valid for German language use \[[@CR41]\]. Furthermore, it has been used already to evaluate PTTD patients with pes planovalgus associated complaints and is considered to be an excellent tool in this circumstance \[[@CR14], [@CR15]\]. The overall (i.e., total) FFI score will be analysed as the primary outcome measure. The subscales of the FFI in the dimensions pain, disability and activity limitation will be analysed separately as secondary outcome measures.

### Pain-Disability-Index (PDI) {#Sec14}

The Pain-Disability-Index (PDI), used to evaluate functional impairment, will also be administered pre- and post-intervention as a secondary outcome \[[@CR43], [@CR55]\]. The PDI is a seven-item inventory designed to measure the degree to which pain interferes with function across a range of seven daily life dimensions (family/home responsibilities, recreation, social activity, occupation, sexual behaviour, self-care and life support activity). Each item ranges from 0 (no interference) to 10 (total interference) resulting in a sum score of 0 to 70 \[[@CR56], [@CR57], [@CR44]\]. It is considered reliable for the assessment of functional impairment and chronic diseases especially in musculoskeletal pathology \[[@CR58], [@CR59]\]. The validity in overuse injuries has previously been proven \[[@CR43], [@CR55]\].

### Visual Analogue Scale (VAS) {#Sec15}

A 100 mm visual analogue scale (VAS) with the endpoints "no pain" and "worst pain possible" is administered before and after the biomechanical assessment to evaluate acute pain levels. It is valid and reliable in terms of the measurement of self-reported pain intensity \[[@CR60]\].

### Biomechanical testing {#Sec16}

Biomechanical testing will take place before and after the intervention. All measurements will be taken with participants barefoot in three situations ("standing", "level walking" and "walking downstairs"). Participants will walk on an even walkway with embedded force plates (AMTI® OR6, Watertown, USA) for ground contact detection and ground reaction force measurements at a self-selected speed. Ten successful walking trials will be collected. In addition, 10 successful trials of descending from two stair steps on the embedded force plates will be collected. This functionally relevant situation is administered to enhance load on the foot structures in a functionally relevant way \[[@CR61], [@CR62]\].

Participants will be prepared with reflective markers at bony landmarks according to a lower body marker set (Vicon® Plug-In-Gait lower body, Oxford, UK) to capture the kinematics and kinetics of hip, knee and ankle joints. A second 4-marker set based on suggestions by Dicharry will be used to measure dynamic navicular drop \[[@CR23]\]. A static measurement will serve as a calibration for preceding dynamic trials. The comparison with the static trial will allow calculation of changes due to the additional load application during walking and on the stairway. A 10 camera setup (Vicon Bonita, Vicon® Motion Systems Ltd., Oxford, UK) will be used with a sampling rate of 200 Hz.

At the same time, the tibialis anterior, peroneal and gastrocnemius (medial and lateral head) muscles will be prepared bilaterally for surface EMG measurements. Localisation of disposable pregelled Al/AgCl bipolar surface electrodes (Ambu®, Medicotest®, DK, type N-00-S, distance from centre to centre: 25 mm) will be carefully determined according to Winter and Yack and the SENIAM procedures \[[@CR63], [@CR64]\]: The longitudinal axes of the electrodes shall be in line with the presumed direction of the underlying muscle fibres. Interelectrode impedance shall be kept below 5 kOhms by means of shaving, light abrasion, degreasing and disinfecting the skin with alcohol. The EMG electrodes will be directly connected to differential pre-amplifiers and taped to the skin. The pre-amplified signals will then be transmitted via shielded cables (fixed to the leg with Velcro straps lattice bracing) to the main amplifier (PowerPack, pfitec®, Endingen, DE). Signals will be 12-bit analogue/digital-converted and stored on a personal computer. The sampling frequency will be set at 2000 Hz.

Signal data processing of kinematic data will calculate a representative mean stride cycle from the 10 collected trials per situation and condition. The kinematic outcome measures will be calculated with the manufacturer's software Vicon Nexus® (Vicon® Motion Systems Ltd., Oxford, UK), and MatLab® (Mathworks Inc., Natick, USA) and will then be transferred to a data spreadsheet for statistical analysis.

Post-processing of EMG signals will include rectification and calculation of one average stride cycle out of 10 consecutive stride cycles. The on-off pattern of muscle activity will then be defined above a threshold of the resting signal plus two standard deviations. Above this threshold the muscle will be considered "on". "Off" is defined after decline of the EMG signal below this threshold. "On" and "off" will be determined automatically by customised software (LabView®-based: Software Imago, pfitec®, Endingen, DE) and checked visually by a person experienced in EMG data processing but blinded to group assignment of the individual trial. This is considered to be a reasonable procedure securing both high standardisation and validity \[[@CR65]\]. Total time of activation (Ttot) will then be calculated as a percentage of total stride time. The onset of activation (Tini) and the time of maximum activation (Tmax) will be extracted and expressed in relation to touchdown in % of stride \[[@CR66], [@CR34], [@CR33], [@CR35]\]. Amplitudes in the gait cycle phases pre-activation (Apre), weight acceptance (Awa), midstance (Ams) and push-off (Apo) will be calculated according to the phase definition by Winter \[[@CR67]\]: Pre-activation is defined as the period from onset of electromyographic activity (see above) to initial touchdown. Weight acceptance is the period of time between initial contact and the following 15 % of the stride period ('early stance'). Midstance is the period from 15 % to 40 % of stride. Push-off is the period of time late in stance from 40 % of stride to toe-off \[[@CR67]\]. The mean amplitude voltage (MAV) per gait cycle phase will be extracted and normalised to the MAV of the entire stride cycle. Hence, Apre, Awa, Ams and Apo are determined relative to the average activity and expressed as a fraction of the average amplitude (=1.0). Data will then be transferred from LabVIEW®-format to a data spreadsheet for plausibility control and statistical analysis.

Signal processing personnel will be blinded to experimental condition. The electronic database will then be checked for plausibility. All measures will be checked by range checks to estimate validity of retrieved quantities. Apparent discordant values will be tracked back to their origin and data analysis will be repeated. The data spreadsheet of all manually collected data like anthropometrics will be printed as a hardcopy. Missing values will be marked, cross-checked, added or corrected if applicable. Random re-evaluation of original data will serve for cross-checking of originally analysed biomechanical data. All outcomes and quantities of kinematic and electromyographic measurements are shown in Table [1](#Tab1){ref-type="table"} (primary, secondary and tertiary outcome measures).Table 1Outcome measuresPrimary outcome measureUnit  • Foot Function Index (FFI) -- total scoresum score \[0--230\]Secondary outcome measuresUnit  • Foot Function Index (FFI) -- subcategory painsum score \[0--90\]  • Foot Function Index (FFI) -- subcategory disabilitysum score \[0--90\]  • Foot Function Index (FFI) -- subcategory activity limitationsum score \[0--50\]Tertiary outcome measuresUnitAdditional assessment of functional impairment and current pain perception  • Pain Disability IndexSum score \[0--70\]  • Visual Analog Scale (VAS) assessing pain (pre-post biomechanical testing)Score \[0--10\]Tertiary outcome measures from biomechanical dataUnitKinematic data from 3D movement analysisDistance  • Dynamic navicular dropMillimeter \[mm\]Kinematic data from 3D movement analysisAngular data: angle at initial contact, maximal manifestation during stance, range  • Foot Progression AngleAngular degree \[°\]  • Forefoot to rearfoot dorsiflexionAngular degree \[°\]  • Forefoot to rearfoot adductionAngular degree \[°\]  • Forefoot to rearfoot supinationAngular degree \[°\]  • Ankle dorsiflexionAngular degree \[°\]  • Ankle adductionAngular degree \[°\]  • Ankle eversionAngular degree \[°\]  (hindfoot with respect to tibia)  • Ankle dorsiflexionAngular degree \[°\]  • Ankle adductionAngular degree \[°\]  • Ankle eversionAngular degree \[°\]  (hindfoot with respect to lab)  • Knee flexionAngular degree \[°\]  • Knee adductionAngular degree \[°\]  • Knee internal rotationAngular degree \[°\]  • Hip flexionAngular degree \[°\]  • Hip adductionAngular degree \[°\]  • Hip internal rotationAngular degree \[°\]Neuromuscular activityEMG of M. tibialis anterior, M. peroneus longus, M. gastrocnemius lateralis/medialis, M. soleus  • Onset of activation% of stride  • Time of maximum activation% of stride  • Total time of activation% of stride  • Normalized amplitude in preactivationarbitrary unit \[uV/uV\]  • Normalized amplitude in weight acceptancearbitrary unit \[uV/uV\]  • Normalized amplitude in mid-stancearbitrary unit \[uV/uV\]  • Normalized amplitude in push-offarbitrary unit \[uV/uV\]Primary, secondary and tertiary outcome measures of this RCT

Data analysis {#Sec17}
-------------

Data will be transferred from Case Report Forms to Microsoft® Excel for Windows (current version) spread sheets and later processed by SPSS® (current version). Biomechanical data will be processed with the outlined software and final quantities will also be transferred to spreadsheets for statistical analysis.

Statistical analysis will be performed descriptively after plausibility control. First, testing of normal distribution (Shapiro-Wilk test) of data will be followed by the calculation of mean, standard deviation and 95 % confidence interval. Primary outcome measure (FFI total score) at measurement points 0, week 6 and week 12 will be analysed by 3x3 Analysis of Variance (ANOVA) with repeated measures identifying differences in the FFI across groups (FOO, FOE, FOS) and test sessions. This also applies for the secondary outcome measures (FFI pain subcategory, FFI disability subcategory and FFI activity limitation subcategory). The primary endpoint will be set at 12 weeks. Biomechanical data will be analysed descriptively. Pre-post comparisons of those tertiary outcome measures will also be performed where indicated after descriptive analysis by 2×2 repeated measures ANOVA (factor group and test day).

Sample size calculation has been based on the outlined protocol with three intervention groups and the same primary outcome as Kulig et al. \[[@CR14], [@CR15]\], where a sample size of *n* = 15 per group (total *N* = 45) was determined based on clinical observation, attrition rate and power analysis. Clinical observation suggested that there is moderate to high inter-subject variability with respect to pain, disability and function (patient's perception). A drop-out rate of 20 % is assumed due to a long intervention period, increase or resolution of symptoms during the intervention, or a need for surgery requiring exit from the study. Power analysis was based on an alpha level of 0.05 and beta of 0.8 resulting in the proposed sample size of 45 \[[@CR38]\].

Based on this reported sample size with the same main outcome and design, an *à priori* calculation of the total sample size was performed leading to a group sample of *n* = 20 (total *N* = 60) according to the following assumptions (Software: G\*Power3, \[[@CR68], [@CR69]\]: test family = F-tests, statistical test = repeated measures ANOVA, effect size = 0.2 (medium), alpha = 0.05, power = 0.82, number of groups = 3, number of measurements = 3, correlation among the repeated measures = 0.5, nonsphericity correction epsilon = 1 and dropouts *n* = 6).

Discussion {#Sec18}
==========

The objective of this randomised trial is the evaluation of the therapeutic benefit of three different non-surgical treatment regimens (foot orthoses only FOO, foot orthoses and eccentric exercise FOE, sham foot orthoses FOS) in patients with pes planovalgus and accompanying complaints. The clinical validity of those therapy regimens will result in important clinical implications.

The lack of evidence for non-surgical treatment strategies emphasises the need for such a trial. Beside the fact that established clinical outcomes will be used to assess clinical efficacy of therapy regimens, the novel aspect of the trial is to integrate biomechanical measurements of lower extremity and foot function.

The development and final set-up of the intervention groups was the subject of great debate between the investigators, the funding agency's international reviewers and the ethics committee. The author/investigator group initially planned foot orthoses as the basic therapy for all three groups. The promising results of the aforementioned RCT by Kulig et al. \[[@CR15]\] justified this approach \[[@CR38]\]. Consequently, according to the best available evidence, foot orthoses were planned for all groups. One group with additional eccentric exercises and one group with additional "traditional" physiotherapy (a regimen of ice, ultrasound, electrotherapy, manual therapy) were planned to assess the additive effect of exercise therapy and physiotherapy. The rationale for eccentric exercises was derived from existing evidence for the treatment of (chronic) tendinopathy \[[@CR51], [@CR50], [@CR52]\]. Physiotherapy was planned to be integrated into this trial because it reflects current physiotherapeutic practice in the daily routine. The reviewers of the funding agency rejected the physiotherapy therapy modality due to lack of any scientific evidence. During the process of ethics approval, the regional ethics committee, acting as the legal authority in Switzerland came to the conclusion that there is also no rationale for foot orthoses since the trial by Kulig et al. did not evaluate foot orthoses against a wait-and-see approach \[[@CR15]\]. They concluded that research ethics allow refraining from foot orthoses in this patient group. Consequently, they requested an untreated control group. The investigator group emphasised that there are frequent dropouts in such a control group and suggested a sham orthosis group as a control. The ethics committee finally approved this idea and the funding agency also accepted the final therapy group definitions.

The rationale for the measurement of the gait mechanics and neuromuscular control in this trial is to gain a comprehensive view on functional changes due to pathology and their plasticity during the intervention. One study has analysed kinematic differences between healthy and PTTD patients in a heel rise movement \[[@CR70]\]. It found that stage II PTTD patients exhibited greater plantar flexion to achieve heel rise compared to healthy controls \[[@CR70]\]. The same study found greater tibialis posterior muscle lengthening during walking and greater hindfoot eversion during stance \[[@CR71], [@CR72]\].

The tibialis posterior muscle is the main muscular stabiliser for active longitudinal arch stabilisation \[[@CR73]\]. Foot orthoses with an arch support have been found to selectively activate the tibialis posterior muscle \[[@CR74]\]. Therefore, it would be the best muscular indicator in the context of pes planovalgus, but measurements of this deep lower leg muscle are not possible with surface electromyography. Accordingly, the trial refrains from using highly invasive techniques, so as to not place study participants at risk. There are reports of synergistic activity of the tibialis posterior muscle and the superficially available peroneus longus muscle \[[@CR29]\]. The approach is, therefore, to evaluate easily available parameters that can be transferred to clinical settings. Further assessment of the tibialis anterior muscle and gastrocnemius (medialis and lateralis) muscles \[[@CR66], [@CR34], [@CR33], [@CR35]\] will be performed to cover the "neuromuscular" dimension that relate to common kinematic movements like dynamic navicular drop, rearfoot eversion, etc.

The analysis of possible functional changes in gait mechanics and neuromuscular control will contribute to an enhanced understanding of functional changes that occur with conservative management. This will enable us to generate theories about the mechanisms possibly involved in the process of symptom relief. Furthermore, a subsequent aim is to optimise conservative management strategies, which may lead to more efficient use of health care resources.
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